F Dx Advisors, Inc. Coherus Bio Sciences, Inc. Transaction History

F Dx Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 17, 2023	SELL	$3.79 - $8.3 $610 - $1,336	-161 Reduced 1.32%	12,062 $51,000
Q4 2022 Feb 09, 2023	BUY	$5.69 - $10.07 $3,175 - $5,619	558 Added 4.78%	12,223 $97,000
Q3 2022 Nov 10, 2022	SELL	$7.17 - $13.87 $13,959 - $27,004	-1,947 Reduced 14.3%	11,665 $112,000
Q2 2022 Aug 03, 2022	BUY	$5.86 - $13.23 $10,184 - $22,993	1,738 Added 14.64%	13,612 $99,000
Q1 2022 May 03, 2022	BUY	$10.92 - $16.41 $129,664 - $194,852	11,874 New	11,874 $153,000
Q4 2021 Feb 01, 2022	SELL	$15.81 - $18.99 $165,641 - $198,958	-10,477 Closed	0 $0
Q3 2021 Oct 08, 2021	SELL	$12.68 - $17.79 $1.49 Million - $2.08 Million	-117,161 Reduced 91.79%	10,477 $168,000
Q1 2020 May 13, 2020	BUY	$11.67 - $22.53 $1.49 Million - $2.88 Million	127,638 New	127,638 $3.87 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on F Dx Advisors, Inc. with notifications on news.